Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis

Septic Shock Clinical Trial

— CLOVERS  

Official title:

Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03434028
• Other study ID #: PETAL03 CLOVERS
• Status: Completed
• Phase: Phase 3
• Start date: March 7, 2018
• Est. completion date: August 24, 2022

Study information

• Verified date: June 2023
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Multicenter, prospective, phase 3 randomized non-blinded interventional trial of fluid treatment strategies in the first 24 hours for patients with sepsis-induced hypotension. The aim of the study is to determine the impact of a restrictive fluids strategy (vasopressors first followed by rescue fluids) as compared to a liberal fluid strategy (fluids first followed by rescue vasopressors) on 90-day in-hospital mortality in patients with sepsis-induced hypotension.

Description:

Primary Hypothesis: Restrictive (vs liberal) fluid treatment strategy during the first 24 hours of resuscitation for sepsis-induced hypotension will reduce 90-day in-hospital mortality.

1. We will emphasize early screening and protocol initiation, and enroll a maximum of 2320 patients with suspected sepsis-induced hypotension.

• All patients will receive at least 1 liter of fluids prior to meeting study inclusion criteria (and no more than 3 liters prior to randomization).

• Patients will be enrolled within 4 hours of meeting study inclusion criteria

• Any type of isotonic crystalloid (normal saline, ringers lactate, or a balanced solution such as plasmalyte) is permitted.

2. Restrictive Fluids (Early Vasopressors) Group

• Norepinephrine will be used as preferred vasopressor and titrated to achieve mean arterial pressure (MAP) between 65 mmHg and 75 mmHg

• "Rescue fluids" may be administered as 500ml boluses if predefined rescue criteria are met

3. Liberal Fluids (Fluids First)

• 2 liter infusion upon enrollment (may forego second liter if MAP/SBP and heart rate are normalized and clinical assessment if patient is fluid replete after the first liter).

• Administer 500ml fluid boluses for fluid triggers until 5 liters administered or development of clinical signs of acute volume overload develop

• "Rescue vasopressors" may be administered after 5 liters of fluid, for development of acute volume overload, or if other predefined rescue criteria are met

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1563
• Est. completion date: August 24, 2022
• Est. primary completion date: May 10, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years

• A suspected or confirmed infection (broadly defined by administration or planned administration of antibiotics)

• Sepsis-induced hypotension defined as systolic blood pressure < 100 mmHg or MAP < 65 mmHg after a minimum of at least 1 liter of fluid (*Fluids inclusive of pre-hospital fluids; blood pressure must be below any known or reported pre-morbid baseline).

Exclusion Criteria:

• More than 4 hours elapsed since meeting inclusion criteria or 24 hours elapsed since admission to the hospital

• Patient already received 3 liters of intravenous fluid (includes prehospital volumes)

• Unable to obtain informed consent

• Known pregnancy

• Hypotension suspected to be due to non-sepsis cause (e.g. hemorrhagic shock)

• Blood pressure is at known or reported baseline level

• Severe Volume Depletion from an acute condition other than sepsis. In the judgment of the treating physician, the patient has an acute condition other than sepsis causing (or indicative) of *severe volume depletion; Examples include: Diabetic ketoacidosis, high volume vomiting or diarrhea, hyperosmolar hyperglycemic state, and nonexertional hyperthermia (heat stroke); severe is defined by the need for substantial intravenous fluid administration as part of routine clinical care

• Pulmonary edema or clinical signs of new fluid overload (e.g. bilateral crackles, new oxygen requirement, new peripheral edema, fluid overload on chest x-ray)

• Treating physician unwilling to give additional fluids as directed by the liberal protocol

• Treating physician unwilling to use vasopressors as directed by the restrictive protocol.

• Current or imminent decision to withhold most/all life-sustaining treatment; this does not exclude those patients committed to full support except cardiopulmonary resuscitation

• Immediate surgical intervention planned such that study procedures could not be followed

• Prior enrollment in this study

Related Conditions & MeSH terms

• Sepsis
• Septic Shock

Intervention

Drug:
• Early Vasopressors
Norepinephrine will be used as preferred vasopressor and titrated to achieve mean arterial pressure (MAP) between 65 mmHg and 75 mmHg. "Rescue fluids" may be administered as 500ml boluses if predefined rescue criteria are met.

Other:
• Early Fluids
Additional 2 liter intravenous fluid infusion upon enrollment (may forego second liter if MAP/SBP and heart rate are normalized and clinical assessment if patient is fluid replete after the first liter). Administer 500ml fluid boluses for fluid triggers until 5 liters administered or development of clinical signs of acute volume overload develop. "Rescue vasopressors" may be administered after 5 liters of fluid, for development of acute volume overload, or if other predefined rescue criteria are met. Any type of isotonic crystalloid (normal saline, ringers lactate, balanced solution such as plasmalyte) is permitted.

Locations

Country	Name	City	State
United States	University of Michigan Medical Center	Ann Arbor	Michigan
United States	University of Colorado Hospital	Aurora	Colorado
United States	Beth Israel Medical Center	Boston	Massachusetts
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina
United States	Medical University of South Carolina	Charleston	South Carolina
United States	University Virginia Medical Center	Charlottesville	Virginia
United States	University of Cincinnati Medical Center	Cincinnati	Ohio
United States	Cleveland Clinic Foundation	Cleveland	Ohio
United States	Ohio State University Wexner Medical Center	Columbus	Ohio
United States	Denver Health Medical Center	Denver	Colorado
United States	St. Joseph Hospital	Denver	Colorado
United States	Duke University Medical Center	Durham	North Carolina
United States	UCSF Fresno	Fresno	California
United States	Penn State Hershey Medical Center	Hershey	Pennsylvania
United States	University of Texas Health Science Center	Houston	Texas
United States	Indiana University Health Methodist Hospital	Indianapolis	Indiana
United States	University of Mississippi Medical Center	Jackson	Mississippi
United States	University of Kentucky	Lexington	Kentucky
United States	Ronald Reagan UCLA	Los Angeles	California
United States	Hennepin County Medical Center	Minneapolis	Minnesota
United States	University of Minnesota Medical Center	Minneapolis	Minnesota
United States	Intermountain Medical Center	Murray	Utah
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Yale New Haven Hospital	New Haven	Connecticut
United States	University Medical Center (LSU)	New Orleans	Louisiana
United States	Montefiore Medical Center	New York	New York
United States	Mt. Sinai Hospital	New York	New York
United States	McKay-Dee Hospital	Ogden	Utah
United States	Temple University Hospital	Philadelphia	Pennsylvania
United States	UPMC Mercy	Pittsburgh	Pennsylvania
United States	UPMC Presbyterian	Pittsburgh	Pennsylvania
United States	UPMC Shadyside	Pittsburgh	Pennsylvania
United States	Maine Medical Center	Portland	Maine
United States	Oregon Health and Science University OHSU	Portland	Oregon
United States	Utah Valley Regional Medical Center	Provo	Utah
United States	VCU Medical Center	Richmond	Virginia
United States	LDS Hospital	Salt Lake City	Utah
United States	University of Utah Health Sciences Center	Salt Lake City	Utah
United States	UCSF San Francisco	San Francisco	California
United States	Harborview Medical Center	Seattle	Washington
United States	Swedish Hospital First Hill	Seattle	Washington
United States	University of Washington Medical Center	Seattle	Washington
United States	Baystate Medical Center	Springfield	Massachusetts
United States	Stanford University Hospital	Stanford	California
United States	University of Arizona	Tucson	Arizona
United States	Wake Forest Baptist Health	Winston-Salem	North Carolina
United States	St. Vincent Hospital	Worcester	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Death Before Discharge Home by Day 90	The primary outcome was death from any cause before discharge home by day 90. Point estimates were from Kaplan-Meier curves. There were 109 deaths and 5 patients with censored data the restrictive fluid group and 116 deaths and 4 patients with censored data in the liberal group. We defined home as the same setting or a setting similar to the one where the patient resided before becoming ill. Thus, if a patient originated from a private residence and was discharged from the hospital to a rehabilitation setting, we assessed for vital status until return to the private residence.Vital status was determined using any of the following methods: medical record review, phone calls to patient, proxy or healthcare facility, review of obituaries, or information from the Centers for Disease Control and Prevention's National Death Index (NDI).	From randomization to discharge home up to and including day 90.
Secondary	Organ Support Free Days	Defined as a patient being alive and without assisted breathing, new renal replacement therapy, or vasopressors (excluding vasopressor use prior to 48 hours). Any day that a patient is alive and without organ support will represent days alive and free of organ support.	28 days after randomization
Secondary	Ventilator Free Days (VFD)	Ventilator-free days is defined to be 28 days minus the duration of mechanical ventilation through day 28. Participants who do not survive to day 28 are assigned zero ventilator-free days.	28 days after randomization
Secondary	Renal Replacement Free Days	The number of calendar days between randomization and 28 days later that the patient is alive and without renal replacement therapy. Patients who died prior to day 28 are assigned zero renal replacement free days.	28 days after randomization
Secondary	Vasopressor Free Days	The number of calendar days between day 2 (eligibility starting 48 hours post randomization) and 26 days later that the patient is alive and without the use of vasopressor therapy. Patients who died prior to day 28 are assigned zero vasopressor free days.	From study day 2 through day 28
Secondary	ICU Free Days	Defined as the number of days spent alive out of the ICU to day 28.	28 days after randomization
Secondary	Hospital Free Days to Discharge Home	Days alive post hospital discharge through day 28. Patients who die on or prior to day 28 are assigned zero hospital free days.	28 days after randomization
Secondary	New Intubation With Invasive Mechanical Ventilation by 28 Days	Patients who receive invasive mechanical ventilation via endotracheal or tracheostomy tube, except those intubated solely for a procedure and extubated within 24 hours, through to study day 28 meet this endpoint. Non-invasive mechanical ventilation will not be included as an outcome. This is a binary outcome.	28 days after randomization
Secondary	Initiation of Renal Replacement Therapy	Patients receiving (new) renal replacement therapy through day 28. Patients with chronic renal replacement therapy initiated prior to the current sepsis illness were not eligible to meet this endpoint.	28 days after randomization
Secondary	Kidney Disease: Change in Creatinine-based Global Outcomes (KIDGO) Score Between Baseline and 72 Hours	Assessment of renal function using the KDIGO staging system (using serum creatinine criteria only) between baseline and 72 hours post randomization to assess for de novo acute kidney injury (AKI) (e.g., meeting criteria for AKI by KDIGO criteria) or worsening AKI (e.g., increasing severity). Patients on chronic renal replacement therapy were not eligible for this endpoint determination.; Scoring of 1-3 (using serum creatinine levels; a higher score indicates worsening kidney function): creatinine level 1.5-1.9 times baseline OR >/= 0.3 mg/dl (>/= 25.5 umol/l) increase; creatinine level 2.0-2.9 times baseline; creatinine level 3.0 times baseline OR increase in serum creatinine to >/=4.0mg/dl (>/= 353 umol/l) OR initiation of renal replacement therapy	72 hours after randomization
Secondary	Change in SOFA (Sepsis Related Organ Failure Assessment) Score	SOFA score was calculated at enrollment and at 72 hours using clinically available data.Total score: 0-4 points; 4 = worst outcome. Values not available at baseline were assumed normal. 72 hours assessment: Closest previously known value was carried forward for missing values. SOFA Scoring Breakout (lower scores mean a better outcome; clinically significant organ failure for CLOVERS was defined as a SOFA score 2 or more points higher than baseline): Coagulation( Platelets, ×10³/µL): Score = 0: >150; 1: Liver (Bilirubin, mg/dL): Score: 0: <1.2; 1: 1.2-1.9; 2: 2.0-5.9; 3: 6.0-11.9; 4: >11.9; Cardiovascular(Hypotension): Score: 0: no hypotension; 1: Mean arterial pressure <70 mmHg; 2: DopamineRenal (Creatinine, mg/dL or urine output, ml/d): Score: 0: <1.2; 1: 1.2-1.9; 3: 2.0-3.4; 3: 3.5-4.9 or <500; 4: >4.9 or <200	72 hours after randomization
Secondary	Development of ARDS	Presence and severity of ARDS is determined using the PaO2/FiO2 ratio or SpO2/FiO2 ratio and confirmation of ARDS through chest x-ray reviews.	7 days after randomization
Secondary	New Onset Atrial or Ventricular Arrhythmia	The occurrence of one or more episodes (sustained for more than 1 minute for SVT and AF, > 15 seconds for VT) during through day 28 will be recorded.	28 days after randomization
Secondary	Death From Any Cause at Any Location by Day 90	Subjects were contacted at day 90 to ascertain their survival status via telephone contact with the patient or family members or by a review of medical records and publicly available data sources.	From randomization to and including day 90